Nothing Special   »   [go: up one dir, main page]

Tajbakhsh et al., 2017 - Google Patents

Effect of hemodialysis on oxidants and antioxidant factors in chronic renal failure

Tajbakhsh et al., 2017

Document ID
11140198737019147487
Author
Tajbakhsh R
Qorbani M
Mehrpour G
Rahimzadeh M
Azimzadeh M
Mirmiranpour H
Publication year
Publication venue
Saudi Journal of Kidney Diseases and Transplantation

External Links

Snippet

The current study was conducted to assess the effect of hemodialysis (HD) on the status of plasma oxidants and antioxidants among patients with end-stage renal disease (ESRD). These parameters can have an influence on the HD process and can also be useful for …
Continue reading at journals.lww.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue

Similar Documents

Publication Publication Date Title
Tajbakhsh et al. Effect of hemodialysis on oxidants and antioxidant factors in chronic renal failure
Annuk et al. Oxidative stress and endothelial function in chronic renal failure
Russo et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy
Link et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients
Deicher et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients
Shema-Didi et al. One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: a randomized placebo-controlled trial
De Vecchi et al. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients
Hsieh et al. Mean corpuscular volume and mortality in patients with CKD
Clermont et al. Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients
Lucchi et al. Erythrocyte susceptibility to oxidative stress in chronic renal failure patients under different substitutive treatments
Kaya et al. Accelerated atherosclerosis in haemodialysis patients; correlation of endothelial function with oxidative DNA damage
Nakae et al. Selective plasma exchange with dialysis in patients with acute liver failure
Dimitrijevic et al. How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients
Stepanova et al. Oxidative stress in peritoneal dialysis patients: association with the dialysis adequacy and technique survival
Uzu et al. Target for glycemic control in type 2 diabetic patients on hemodialysis: effects of anemia and erythropoietin injection on hemoglobin A1c
Lorenz et al. Acetate-free, citrate-acidified bicarbonate dialysis improves serum calcification propensity—a preliminary study
Deo et al. Naphthalene ball poisoning: a rare cause of acquired methaemoglobinaemia
Joksimovic Jovic et al. Erythropoietin resistance development in hemodialysis patients: the role of oxidative stress
Günal et al. The assessment of oxidative stress on patients with chronic renal failure at different stages and on dialysis patients receiving different hypertensive treatment
Mimić-Oka et al. Evaluation of oxidative stress after repeated intravenous iron supplementation
Swarnalatha et al. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress
Nafady et al. Oxidative stress in pediatric patients with β thalassemia major
Elalfy et al. Effect of antioxidant therapy on hepatic fibrosis and liver iron concentrations in β-thalassemia major patients
Stange et al. Industrial stabilizers caprylate andN-acetyltryptophanate reduce the efficacy of albumin in liver patients
Ramakrishna et al. Effect of reuse of polysulfone membrane on oxidative stress during hemodialysis